Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer.
Dang C, Gianni L, Romieu G, Dirix L, Campone M, Citron M, Zamagni C, Krop I, Xu N, Smitt M, Suter T. Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer. Journal Of Clinical Oncology 2012, 30: 532-532. DOI: 10.1200/jco.2012.30.15_suppl.532.Peer-Reviewed Original ResearchEarly-stage HER2-positive breast cancerLeft ventricular ejection fractionHER2-positive breast cancerAnthracycline-based chemotherapyPhase II studyT-DM1Breast cancerCardiac eventsII studyCardiac safetyInterim analysisDoxorubicin/cyclophosphamideOpen-label studyPrevious phase IIVentricular systolic dysfunctionSignificant cardiac eventsVentricular ejection fractionT-DM1 treatmentCo-primary endpointsPhase IICardiac AEsNeoadjuvant settingNeoadjuvant therapySystolic dysfunctionAdverse events